AI Science Tracker

Valar Labs

1 discovery from 2026

Discoveries

CHAI image-only histology biomarker stratifies metastatic hormone-sensitive prostate cancer outcomes in independent trial data

A computational histology AI platform built a prognostic signature from diagnostic whole-slide images in 507 CHAARTED participants and evaluated the locked signature in 684 ENZAMET participants. In the independent ENZAMET cohort, the unfavorable-risk group had worse overall survival (HR 2.6, 95% CI 2.0–3.4) and progression-free survival (HR 2.2, 95% CI 1.7–2.7); associations remained after adjustment for clinical variables. The article also reports treatment-interaction analyses, but this retrospective secondary analysis does not establish prospective treatment-selection benefit.

Technology: Computational Histology Artificial Intelligence (CHAI) platform

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: In the independent ENZAMET cohort, the unfavorable-risk group had worse overall survival (HR 2.6, 95% CI 2.0–3.4) and progression-free survival (HR 2.2, 95% CI 1.7–2.7); associations remained after adjustment for clinical variables.
  • Still unknown: The locked image-only biomarker was independently evaluated across two prospective randomized-trial datasets, but this article is a post hoc secondary analysis, not a prospective biomarker-directed treatment trial. The treatment-interaction result is suggestive and does not prove that choosing triplet therapy by this score improves outcomes. No clinical deployment or benefit claim is made. Primary journal abstract checked; no independent replication assessed.
  • AI role: CHAI extracted quantitative histomorphologic features from H&E diagnostic whole-slide images and learned an image-only risk signature on CHAARTED data; the locked signature was tested in ENZAMET. Humans specified cohorts/endpoints and analyzed the trial outcomes.

Evidence sources: https://ascopubs.org/doi/10.1200/PO-26-00321

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.